RT Journal Article
SR Electronic
A1 Boltz, Kathy
T1 ARCHER 1009 Subset Analysis and LUX-8 Lung: Erlotinib Compared With Dacomitinib or Afatinib
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 8
SP 5
OP 6
DO 10.1177/1559897715588077
UL http://mdc.sagepub.com/content/15/8/5.abstract
AB The subgroup of patients with the EGFR-activating mutation in exon 19 or 21 appeared to have a favorable trend for dacomitinib vs erlotinib in progression-free survival. Afatinib was favored over erlotinib for second-line treatment of advanced squamous cell carcinoma in terms of progression-free survival, overall response rate, and disease control rate.